Blood test could revolutionize Alzheimer's diagnosis at your Doctor's office
NCT ID NCT07666113
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a blood test that measures specific proteins (pTau217) can help primary care doctors diagnose Alzheimer's disease in people with memory concerns. Researchers will compare the test's accuracy against standard evaluations and track how it changes doctors' decisions and patient outcomes over four years. The goal is to make Alzheimer's diagnosis faster, less invasive, and more accessible.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Blood test measuring pTau217 and pTau217/Aβ42 levels
What this could lead to
If successful, this blood test could help primary care doctors diagnose Alzheimer's earlier and more accurately, reducing the need for specialist referrals and invasive tests.
What could go wrong
This is an early-stage study with only 240 participants. The test may not be accurate enough in real-world primary care settings, and results may not apply to all populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UZ Leuven/KU Leuven
RECRUITINGLeuven, 3000, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••